| 摘要 |
Disclosed in the use of a 40 mg dose of adalimumab in the manufacture of a pharmaceutical composition for maintaining or decreasing a modified Total Sharp Score (mTSS) of a subject having psoriatic arthritis, ankylosing spondylitis, or juvenile rheumatoid arthritis following treatment with the medicament, wherein pharmaceutical composition is subcutaneously administrable to the subject according to a biweekly dosing regimen. |
